© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
Affiliations of authors: Oncology Research Network, David Geffen School of Medicine, and Division of Hematology/Oncology, University of California, Los Angeles (MDP, DWN. RP, EQ, DJS); Breast Cancer International Research Group, Edmonton, Alberta, Canada (TP, WE, PF, JC, DT, MS, AR, SB, DR, MAL); Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland (TP); University of Southern California Keck School of Medicine, Los Angeles, CA (MFP).
Correspondence to: Dennis J. Slamon, MD, PhD, University of California, Los Angeles, Peter Ueberroth Bldg., 3360B, 10945 Le Conte Ave., Los Angeles, CA 90095-7077 (e-mail: dslamon{at}mednet.ucla.edu)
Background: Preclinical data indicate that docetaxel, platinum salts, and the combination of both drugs are highly synergistic with the anti-HER2 antibody trastuzumab. The University of California at Los Angeles-Oncology Research Network (UCLA-ORN) and the Breast Cancer International Research Group (BCIRG) have conducted two phase II studies to evaluate docetaxel and trastuzumab in combination with either cisplatin or carboplatin for the treatment of women with advanced breast cancer that overexpresses HER2. Methods: Each study enrolled 62 patients with HER2-overexpressing tumors. Patients received a median of six cycles of docetaxel at 75 mg/m2 of body surface area and cisplatin (BCIRG 101 study) at 75 mg/m2 or carboplatin (UCLA-ORN study) at AUC = 6 mg/mL · min given on day 1 and then every 21 days. Trastuzumab was given on day 1, cycle 1 (4 mg/kg) and then continued weekly at 2 mg/kg for 1 year or until disease progression. Tumor measurements were obtained at baseline, after three cycles of chemotherapy, and then every 3 months. HER2 gene amplification was determined by fluorescence in situ hybridization. Results: Patient characteristics were comparable between trials with the exception that 15% of the patients in the UCLA-ORN study had received previous adjuvant taxane therapy. Both regimens were well tolerated, with manageable toxicities. Hematologic toxicities were more frequent in patients in the UCLA-ORN study than in patients in the BCIRG 101 study, whereas the reverse pattern was observed for non-hematologic toxicities. One patient in each study developed reversible congestive heart failure. Responses were observed in 49 of 62 patients in the BCIRG 101 study (overall response rate = 79%, 95% confidence interval [CI] = 66% to 89%) and in 34 of 59 evaluable patients in the UCLA-ORN study (overall response rate = 58%, 95% CI = 44% to 70%). Median times to progression were 9.9 months (95% CI = 8.3 to 13.1 months) and 12.7 months (95% CI = 8.6 to 15.5 months) for patients in the BCIRG 101 and UCLA-ORN studies, respectively. Overall response rates were higher and median time to progression was longer in the subset of patients whose tumors harbored HER2 gene amplification. Conclusion: Combinations of docetaxel, a platinum salt, and trastuzumab are feasible and active in patients with advanced breast cancers that overexpress HER2. The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- HERe-2 Stay: The Continuing Importance of Translational Research in Breast Cancer
- George W. Sledge, Jr.
J Natl Cancer Inst 2004 96: 725-727.[Extract] [Full Text] [PDF]
Related Article in JNCI
- Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
- Mark D. Pegram, Gottfried E. Konecny, Carminda O'Callaghan, Malgorzata Beryt, Richard Pietras, and Dennis J. Slamon
J Natl Cancer Inst 2004 96: 739-749.[Abstract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  K. Bullock and K. Blackwell Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer Oncologist, May 1, 2008; 13(5): 515 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Hudis Trastuzumab -- Mechanism of Action and Use in Clinical Practice N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51. [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, X. Martin, V. Trillet-Lenoir, et al. Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial J. Clin. Oncol., July 1, 2007; 25(19): 2678 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Yde, M. Gyrd-Hansen, A. E. Lykkesfeldt, O.-G. Issinger, and J. Stenvang Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death Mol. Cancer Ther., June 1, 2007; 6(6): 1869 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Limentani, A. M. Brufsky, J. K. Erban, M. Jahanzeb, and D. Lewis Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancer J. Clin. Oncol., April 1, 2007; 25(10): 1232 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer Oncologist, March 1, 2007; 12(3): 253 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jackisch HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy Oncologist, September 1, 2006; 11(suppl_1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Menendez, I. Mehmi, and R. Lupu Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression J. Clin. Oncol., August 10, 2006; 24(23): 3735 - 3746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Robert, B. Leyland-Jones, L. Asmar, R. Belt, D. Ilegbodu, D. Loesch, R. Raju, E. Valentine, R. Sayre, M. Cobleigh, et al. Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2786 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chia, M. Clemons, L.-A. Martin, A. Rodgers, K. Gelmon, G. R. Pond, and L. Panasci Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial J. Clin. Oncol., June 20, 2006; 24(18): 2773 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Menotti, A. Cerretani, and G. Campadelli-Fiume A Herpes Simplex Virus Recombinant That Exhibits a Single-Chain Antibody to HER2/neu Enters Cells through the Mammary Tumor Receptor, Independently of the gD Receptors. J. Virol., June 1, 2006; 80(11): 5531 - 5539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hurley, P. Doliny, I. Reis, O. Silva, C. Gomez-Fernandez, P. Velez, G. Pauletti, J. E. Powell, M. D. Pegram, and D. J. Slamon Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced Breast Cancer J. Clin. Oncol., April 20, 2006; 24(12): 1831 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Neyt, J. Albrecht, and V. Cocquyt An economic evaluation of Herceptin(R) in adjuvant setting: the Breast Cancer International Research Group 006 trial Ann. Onc., March 1, 2006; 17(3): 381 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bali, M. Pranpat, R. Swaby, W. Fiskus, H. Yamaguchi, M. Balasis, K. Rocha, H.-G. Wang, V. Richon, and K. Bhalla Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 Clin. Cancer Res., September 1, 2005; 11(17): 6382 - 6389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baselga and C. L. Arteaga Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Britten Targeting ErbB receptor signaling: A pan-ErbB approach to cancer Mol. Cancer Ther., October 1, 2004; 3(10): 1335 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Perez Carboplatin in Combination Therapy for Metastatic Breast Cancer Oncologist, September 1, 2004; 9(5): 518 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Sledge Jr. HERe-2 Stay: The Continuing Importance of Translational Research in Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 725 - 727. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749. [Abstract] [Full Text] [PDF]
|
|